Table 1.
Patient and treatment characteristics.
| Characteristics | n = 68 |
|---|---|
| Sex | |
| Male/female | 50 (74%)/18 (26%) |
| Age (years) | 75 (IQR 71–80) |
| <75/≥75 | 31 (46%)/37 (54%) |
| Tumor size (cm) | |
| ≤5/>5 | 43 (63%)/25 (37%) |
| Number of tumors | |
| Solitary/multiple/missing | 45 (66%)/19 (28%)/4 (6%) |
| Node metastases | |
| No/yes | 64 (94%)/4 (6%) |
| Performance Status | |
| 0/1/2 | 40 (59%)/21 (31%)/7 (10%) |
| Bleeding from tumors | |
| No/yes | 40 (59%)/28 (41%) |
| Treatment methods | |
| RT | 6 (9%) |
| RT + surgery | 7 (10%) |
| RT + chemotherapy ± immunotherapy | 42 (62%) |
| RT + surgery + chemotherapy a ± immunotherapy b | 13 (19%) |
| Irradiation field | |
| Local/Total scalp | 48 (71%)/20 (29%) |
| Irradiation methods | |
| IMRT/3DCRT or electron beams | 27 (40%)/41 (60%) |
| Total dose (Gy) | 66 (IQR 60–70) |
| EQD2 (Gy) | 66 (IQR 60–70) |
RT = radiation therapy, IMRT = intensity-modulated radiation therapy, 3DCRT = three-dimensional conformal radiation therapy, EQD2 = equivalent dose in a 2 Gy fraction with α/β = 10 Gy, IQR = interquartile range. a: The most common schedule is weekly dosing for 3 weeks followed by a 1-week break. b: Intratumoral or arterial injection of interleukin-2 at the same time as radiation therapy.